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Boston, Massachusetts; Miami, Florida; and Baltimore, MarylandOBJECTIVES This study sought to determine whether arterial inﬂammation measured by 18F-ﬂuoro-
deoxyglucose positron emission tomography (18F-FDG-PET) improves prediction of cardiovascular dis-
ease (CVD) beyond traditional risk factors.
BACKGROUND It is unknown whether arterial 18F-FDG uptake measured with routine PET imaging
provides incremental value for predicting CVD events beyond Framingham risk score (FRS).
METHODS We consecutively identiﬁed 513 individuals from 6,088 patients who underwent 18F-FDG-
PET and computed tomography (CT) imaging at Massachusetts General Hospital between 2005 and 2008
and who met additional inclusion criteria: $30 years of age, no prior CVD, and free of cancer. CVD events
were independently adjudicated, while blinded to clinical data, using medical records to determine inci-
dent stroke, transient ischemic attack, acute coronary syndrome, revascularization, new-onset angina,
peripheral arterial disease, heart failure, or CVD death. FDG uptake was measured in the ascending aorta
(as target-to-background-ratio [TBR]), while blinded to clinical data.
RESULTS During follow-up (median 4.2 years), 44 participants developed CVD (2 per 100 person-
years at risk). TBR strongly predicted subsequent CVD independent of traditional risk factors (hazard ratio:
4.71; 95% conﬁdence interval [CI]: 1.98 to 11.2; p < 0.001) and (hazard ratio: 4.13; 95% CI: 1.59 to 10.76;
p ¼ 0.004) after further adjustment for coronary calcium score. Addition of arterial PET measurement to
FRS scores improved the C-statistic (mean  standard error 0.62  0.03 vs. 0.66  0.03). Further, incor-
poration of TBR into a model with FRS variables resulted in an integrated discrimination of 5% (95% CI:
0.36 to 9.87). Net reclassiﬁcation improvements were 27.48% (95% CI: 16.27 to 39.92) and 22.3% (95% CI:
11.54 to 35.42) for the 10% and 6% intermediate-risk cut points, respectively. Moreover, TBR was
inversely associated with the timing of CVD (beta 0.096; p < 0.0001).
CONCLUSIONS Arterial FDG uptake, measured from routinely obtained PET/CT images, substan-
tially improved incident CVD prediction beyond FRS among individuals undergoing cancer surveillance
and provided information on the potential timing of such events. (J Am Coll Cardiol Img 2013;6:1250–9)
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1251ools such as the Framingham risk score and CT imaging for oncological evaluation at the
(FRS) are widely used to assess risk of
cardiovascular disease (CVD) and provide
a basis for the determination of optimal
primary prevention strategies (1,2). However, the
majority of CV events occur in individuals who are
stratiﬁed as having low to intermediate risk by such
risk assessment tools (3–5). Accordingly, better risk
assessment tools are needed. Although the added
beneﬁt of blood biomarkers has been documented
over the years, no more than modest improvements
over traditional risk factors for predicting CV events
have been observed (3,5–7), thus prompting interest
in the use of imaging biomarkers.See page 1260
A B B R E V I A T I O N S
A N D A C R O N YM S
CAC = coronary artery calcium
CT = computed tomography
CVD = cardiovascular disease
18F-FDG-PET = 18F-ﬂuoro-
deoxyglucose positron
emission tomography
FRS = Framingham risk score
hs-CRP = high-sensitivity
C-reactive protein
NRI = net reclassiﬁcation index
PAD = peripheral arterial disease
SUV = standardized
uptake value
TBR = target-to-background
ratio18F-ﬂuorodeoxyglucose positron emission tomo-
graphy (18F-FDG-PET), an imaging modality
that is routinely used for cancer surveillance, allows
quantiﬁcation of 18F-2-deoxy-D-glucose uptake
within the artery wall (a correlate of atherosclerotic
inﬂammation), which has emerged as a marker of
atherosclerosis (8,9). Although studies show evi-
dence of an association between increased arterial
FDG uptake and vascular events observed in a
population of individuals with active cancer (10,11),
no prior study has directly evaluated its incremental
predictive value over traditional risk factors and
none has evaluated the utility of the signal on
cancer-free patients not currently receiving cancer
chemotherapy. Accordingly, we evaluated the in-
cremental utility of arterial FDG uptake, measured
using PET/computed tomography (CT) for pre-
dicting incident CVD. To do so, we identiﬁed
cancer-free patients undergoing routine PET/CT
scans for cancer surveillance and tested the hy-
pothesis that the FDG-PET signal improves pre-
diction of incident CV events.
METHODS
Study population. Study participants (N ¼ 513)
were consecutively identiﬁed from a database of
6,088 patients who had undergone 18F-FDG-PETFrom the *Cardiac MR PET CT Program, Department of Imaging and D
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through 2008. Pre-deﬁned inclusion criteria were:
1) absence of prior cancer diagnosis or remission
from cancer at the time of PET imaging and
throughout the follow-up period; 2) $30 years of
age; 3) no prior history of CVD; and 4) absence of
acute or chronic inﬂammatory or autoimmune
disease (based on documented medical history) or
use of chronic anti-inﬂammatory therapy. Partici-
pants were required to have at least 3 clinical visit
notes (spanning $1 year) to ensure that sufﬁcient
clinical data were available (including that of the
FRS for 10-year CVD risk components such as age
[years], sex, systolic blood pressure [mm Hg],
current smoking [within 1 year], diabetes, total
cholesterol [mg/dl], and high-density lipoprotein
cholesterol [mg/dl]) (12) to determine clinical sta-
tus around the time of PET imaging. PET
and CT images were collected for blinded
analysis, and clinical data were routed for
blinded event adjudication by an adjudi-
cation committee (Fig. 1). The study
protocol was approved by the local human
research committee.
Outcome events. CVD was herein deﬁned
according to the manner used to determine
FRS risk categories (12): incident ischemic
stroke or transient ischemic attack, acute
coronary syndrome, revascularization (cor-
onary, carotid, or peripheral), new-onset
angina, peripheral arterial disease (PAD),
heart failure, or CVD death. Events were
clinically adjudicated by 2 cardiologists
using clinically available records (Online
Appendix).
PET/CT protocol and image analysis. Whole-body
FDG-PET imaging was performed per clinical
protocol using a Biograph 64 (Siemens, Forchheim,
Germany) or similar system. FDG was adminis-
tered at approximately 370 MBq (10 mCi) intra-
venously after an overnight fast. PET images were
acquired in 3-dimensional mode approximately 60
min later. Patients were imaged in the supine po-
sition, and images were obtained over 15 to 20 min.
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Figure 1. Schematic Diagram of Patient Selection
Analysis cohort was derived from a database of patients who underwent whole-body 18F-ﬂuorodeoxyglucose positron emission tomography
(18F-FDG-PET) scans for clinical indications. The 18F-FDG-PET imaging at the time the participants met inclusion and exclusion criteria serve as
the start of follow-up. All exclusions were made prior to unblinding of imaging data. Missing images represent patients who were eligible but
had missing PET or computed tomography (CT) images. Available data insufﬁcient for clear adjudication represent patients who experienced
other events that did not meet adjudication criteria for cardiovascular disease (CVD) (2 patients excluded because events could not be clearly
adjudicated based on available clinical data and 1 patient excluded due to development of right carotid dissection during follow-up, which
neither qualiﬁed for incident CVD or no CVD). ACS ¼ acute coronary syndrome; MGH ¼ Massachusetts General Hospital; PAD ¼ peripheral
arterial disease; TIA ¼ transient ischemic attack.
Figure 2. FDG Uptake Measurement
FDG uptake was evaluated within the wall of the aorta on axial images. At each axial
section, a region of interest (ROI) was drawn around the wall of the aorta and the maximum
standardized FDG uptake value (SUVmax) was recorded. The thickness of each axial slice was
approximately 5 mm. Subsequently, the target-to-background ratio (TBR) was calculated by
dividing the mean of all axial slice SUVmax (approximately 6 to 8 slices per patient) by the
venous blood SUVmax obtained from the superior vena cava (average of 10 ROIs) to correct
for the blood compartment contribution. Ao ¼ aorta; LM ¼ left main artery; SVC ¼ superior
vena cava; other abbreviations as in Figure 1.
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1252(120 keV, 50 mAs) was used for attenuation
correction prior to the PET scan.
FDG uptake measurement. PET-CT images were
batch-analyzed by an investigator blinded to the pa-
tients’ clinical information according to previously
described methods (13). FDG uptake was evaluated
within the wall of the ascending aorta and superior
vena cava (asmaximum andmean standardized FDG
uptake value [SUVmax and SUVmean, respectively])
approximately every 5 mm on axial images, a location
with excellent reproducible measures of FDG uptake
(14). Subsequently, the target-to-background ratio
(TBR) was reported (ratio of the average arterial to
blood axial slice SUVmax) to correct for the blood
compartment contribution (15). TBR is a reproduc-
ible method (14,15) for measuring arterial FDG
uptake that has been shown to correlate with histo-
logical markers of inﬂammation (Fig. 2) (9,16) and
has been used in a majority of other studies (17–19).
Coronary artery calcium score assessment. Coro-
nary artery calcium (CAC) score was evaluated by
a separate group of investigators (E.C. and U.H.)
than those who performed the PET/CT analyses
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1253using standardized methods (20) while blinded to
clinical information and PET data. Details are
provided in the Online Appendix.
Statistical analysis. Descriptive data are presented
as mean  SD for continuous parametric variables,
median (interquartile range [IQR]) for continuous
nonparametric data, and frequency with proportions
for nominal variables, as appropriate. The Fisher
exact test was used to evaluate differences in pro-
portions. For comparison of continuous variables,
Student t test was used for parametric and Mann-
Whitney U test for nonparametric data. Kaplan-
Meier estimates of CVD-free events of patients
stratiﬁed by tertiles of FDG uptake expressed as
TBR or SUV were calculated. We prospectively
sought to threshold TBR data based on data
distribution. We subsequently thresholded TBR
data into tertiles for 2 reasons: 1) tertiles have a
better model ﬁt compared with a median cut point;
and 2) tertiles will not reduce statistical power
signiﬁcantly compared with using more than 3
thresholds. Cox proportional hazards regression was
used to calculate hazard ratios and 95% conﬁdence
interval. Additionally, the incremental value of TBR
beyond the FRS components was assessed by
the following methods: 1) concordance probability
estimate, a C-statistic for data with censoring (21);
and 2) net reclassiﬁcation improvement (NRI)
applied to survival data (22). The association be-
tween TBR and the timing of CVD was also eval-
uated using a linear regression analysis with TBR as
the outcome and timing of CVD as ordinal pre-
dictor. Further, we modeled CAC score using 3
categories (0 to 10, 11 to 99, and $100) (23). See
the Online Appendix for details on CAC assess-
ment. All analyses were performed using SAS 9.2
(Cary, North Carolina). A 2-sided p value <0.05
was considered statistically signiﬁcant. Additional
details regarding the statistical analysis is provided
in the Online Appendix.
RESULTS
Baseline characteristics of the entire cohort and
subgroups are shown in Table 1 and Online
Tables S1 and S2. Distribution of risk factors
including TBR and CAC was similar between the
full cohort and the subgroup with complete FRS
variables. Overall, 44 participants developed CVD
(rate 2 per 100 person-years at risk) in 6.5 years
(median 4.2 years; range 0.02 to 6.55). Major CV
events (acute myocardial infarction, ischemic stroke,
and arterial revascularization) were observed at a rate
of 1.49 per 100 person-years of follow-up. In thesubgroup of cancer survivors or patients with previ-
ous history of cancer (n ¼ 429), 28 developed CVD
(rate 1.65 per 100 person-years at risk). Among the
cancer-naive population (n ¼ 84), 16 developed
CVD (rate 5 per 100 person-years at risk). The
median follow-up period was 4.2 years (range 0.02 to
6.55 years, measured from the participants’ index
FDG-PET imaging to their latest clinical follow-up
or electronic medical record on ﬁle as of May 8,
2012, or development of any CVD).
CV events. CVevents were adjudicated as follows: 21
acute coronary syndrome events (17 acute myocardial
infarctions and 4 unstable angina), 17 coronary re-
vascularizations, 2 ischemic strokes, 2 transient
ischemic attacks, 7 nonischemic strokes, 1 carotid
revascularization, 6 new-onset angina (1 with and 5
without occlusive disease documented on invasive
coronary angiogram), 4 new diagnosis of PAD, 2
peripheral revascularizations secondary to PAD, and
2 subsequent CV deaths due to acute myocardial
infarction. Additionally, 4 subsequent non-CV
deaths were registered during the follow-up period.
Cox regression. For the entire cohort, participants in
the highest TBR tertile ($2.2) had an increased risk
for CVD compared with individuals in the lowest
TBR tertile (#1.84): 4.71 (IQR: 1.98 to 11.2; p ¼
0.0004), after adjustment for age and CV risk factors
(Fig. 3). After further adjustment for CAC score,
the association remained robust with a hazard ratio
of 4.13 (IQR: 1.59 to 10.76; p ¼ 0.004). Similar
observations were made when CVD outcomes were
restricted to major CV events (adjusted CVD risk
was higher in patients in the highest TBR tertile
compared with the lowest tertile: 2.95 [IQR: 1.08 to
8.06; p ¼ 0.035]). With the uncorrected arterial
PET measurement (i.e., the aortic SUVmax without
dividing by venous background SUVmax), similar
data were yielded: an increased adjusted CVD risk
was observed in patients in the highest tertile
($2.29) versus lowest tertile (#1.83), 2.67 (IQR:
1.02 to 6.97; p ¼ 0.04) (Online Table S3).
As anticipated, CAC measured on nongated CT
scans was observed to be predictive of CVD. CAC
scores of 11 to 99 and $100 were associated with a
3.45- (IQR: 1.56 to 7.6; p ¼ 0.002) and 3.02- (1.29
to 7.05; p ¼ 0.01) fold higher CVD risk compared
with CAC scores of #10. Moreover, individuals
with higher TBR remained at greater risk for CVD
after adjustment for FRS variables and CAC score
(5.76; IQR: 1.79 to 18.57; p ¼ 0.0003).
The FDG-PET/CT signal provided prognostic
information in both cancer survivors as well as
cancer-naive individuals. An intertertile increase in
TBR was associated with an increased adjusted
Table 1. Baseline Characteristics
Full Cohort
(N [ 513)
Participants Without
Subsequent CVD
(n [ 469)
Subjects With
Subsequent CVD
(n [ 44) p Value
Age, yrs 55 (45–66) 54 (44–65) 67 (61–78) <0.001
Male 215 (42) 196 (42) 19 (43) 0.87
Current smoker 55 (11) 42 (9) 13 (30) <0.001
Body mass index, kg/m2* 27 (23–31) 26 (23–31) 27 (25–31) 0.26
Hypertension 181 (35) 155 (33) 26 (59) <0.001
Hyperlipidemia 143 (28) 125 (27) 18 (41) 0.05
Diabetes 46 (9) 38 (8) 8 (18) 0.046
Statin users 103 (20) 86 (18) 17 (39) 0.003
Antihypertensive therapy 182 (35) 154 (33) 28 (64) <0.001
FDG uptake (TBR) 2.0 (0.28) 1.96 (1.79–2.15) 2.19 (1.94–2.32) <0.001
Systolic blood pressure* 123  15 123  15 126  13 0.16
Lipid proﬁle*
Total cholesterol 192  43 193  44 186  39 0.40
Triglycerides 109 (79–156) 100 (73–150) 130 (86–175) 0.05
High-density lipoprotein 57  18 58  18 50  14 0.005
Low-density lipoprotein 111  37 111  38 109  33 0.70
FRS, 10-yr % risk of general CVD* 9.6 (4.75–18.25) 9 (4–17) 18.8 (10.65–27.45) <0.001
ATP III 10-yr risk categories, %
<10 134 (51.54) 125 (56.8) 9 (22.5) <0.001
10–20 71 (27.31) 58 (26.4) 13 (32.5)
>20 55 (21.15) 37 (16.8) 18 (45)
<6 77 (29.62) 74 (33.6) 3 (7.5) <0.001
6–20 128 (49.23) 109 (49.6) 19 (47.5)
>20 55 (21.15) 37 (16.8) 18 (45)
CAC score* 0 (0–15.89) 0 (0–6.36) 19.13 (0–82) <0.0001
0–10 329 (73.44) 313 (75.6) 16 (47.06)
11–99 61 (13.62) 51 (12.32) 10 (29.41)
$100 58 (12.95) 50 (12.08) 8 (23.53) 0.0001
Race
White 464 (90.45) 424 (90.4) 40 (90.91)
Black or African American 17 (3.31) 16 (3.4) 1 (2.27)
Asian 14 (2.73) 12 (2.6) 2 (4.55) 0.86
Hispanic 17 (3.31) 16 (3.4) 1 (2.27)
American Indian 1 (0.19) 1 (0.21) 0
Continued on the next page
Figueroa et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 2 , 2 0 1 3
Arterial Inﬂammation and CV Risk D E C E M B E R 2 0 1 3 : 1 2 5 0 – 9
1254(for age and risk factors, including CAC) CVD risk
in both cancer-naive individuals (4.26; IQR: 1.60 to
11.32; p ¼ 0.004) as well as cancer survivors (2.06;
IQR: 1.12 to 3.78; p ¼ 0.02). For the subgroup
analyses, no effect modiﬁcations by previous cancer
therapies were observed (Online Table S4).
Association between FDG uptake and timing of
CVD. Arterial PET signals provide information
regarding the potential timing of subsequent CVDevents. Individuals with the highest TBRs were
more likely to experience near-term CVD. The
mean TBR (SD) in each of the groups of individuals
who developed CVD at 0 to 6 months, 7 to 24
months, and >24 to 79 months and no events in 79
months were 2.27 (0.34), 2.16 (0.29), 2.12 (0.23),
and 1.98 (0.28), respectively (Fig. 4). Arterial
inﬂammation (TBR) was inversely related to the
timing of CVD (beta 0.096; p < 0.0001).
Table 1. Continued
Full Cohort
(N [ 513)
Participants Without
Subsequent CVD
(n [ 469)
Subjects With
Subsequent CVD
(n [ 44) p Value
Prior history of cancer 429 (83.63) 401 (86) 28 (64)
Cancer type
None 84 (16.37) 68 (14.5) 16 (36.36)
Lymphoma 189 (36.84) 182 (38.8) 7 (15.91)
Gynecologic 83 (16.18) 79 (16.8) 4 (9.09) <0.001
Gastrointestinal 49 (9.55) 43 (9.2) 6 (13.64)
Lung 20 (3.9) 16 (3.4) 4 (9.09)
Head and neck 38 (7.41) 36 (7.7) 2 (4.55)
Skin 23 (4.48) 21 (4.5) 2 (4.55)
Multiple 22 (4.29) 19 (4) 3 (6.82)
Male reproductive 3 (0.58) 3 (0.64) 0
Other (blood, synovial) 2 (0.39) 2 (0.43) 0
Cancer treatments 387 (72.9) 366 (78) 21 (47.7)
None 126 (24.56) 103 (22) 23 (52.27)
Chemotherapy 136 (26.51) 132 (28) 4 (9.09)
Radiation 36 (7) 33 (7) 3 (6.82)
Chemotherapy þ radiation 201 (38.2) 187 (39.87) 14 (31.82)
Radiation to chest 93 (18.13) 83 (17.7) 10 (22.73) <0.001
Immunotherapy (interferon; IL-2; G-CSF) 5 (0.97) 5 (1.1) 0
Chemotherapy þ immunotherapy 1 (0.19) 1 (0.21) 0
Radiation þ immunotherapy 5 (0.97) 5 (1.1) 0
Chemotherapy þ radiation
þ immunotherapy
3 (0.58) 3 (0.64) 0
Time interval between ﬁnal
cancer therapy and index PET, yrs
1.8 (1–3.5) 1.8 (1–3.4) 2 (0.61–5) 0.67
Time interval between ﬁnal
cancer therapy and CVD event, yrs
5.2 (2.3–7.4) n/a 5.20 (2.3–7.4) n/a
Values are median (IQR), n (%), or mean  SD. p Values are for the comparisons between participants with and without subsequent CVD. *Number of participants with
available data on FRS ¼ 260, CAC ¼ 448, body mass index ¼ 508 for the full cohort; CAC ¼ 414 for the subgroup without CVD; CAC ¼ 34 for the subgroup with CVD.
ATP III ¼ Adult Treatment Panel III; CAC ¼ coronary artery calcium; CVD ¼ cardiovascular disease; FDG ¼ ﬂuorodeoxyglucose; FRS ¼ Framingham risk score; G-CSF ¼
granulocyte colony-stimulating factor; IL-2 ¼ interleukin 2; IQR ¼ interquartile range; n/a ¼ not applicable; PET ¼ positron emission tomography; TBR ¼ target-to-
background ratio.
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1255Risk discrimination. With the data from the sub-
group with complete data available for calculation of
FRS (N ¼ 260 individuals), the addition of FDG
uptake to FRS scores modeled as continuous vari-
ables improved risk discrimination (concordance
probability estimate or C-statistic [standard error])
over 6.5 years of follow-up: 0.66 (0.03) versus 0.62
(0.03). Further, incorporation of TBR into the
model with FRS variables resulted in an inte-
grated discrimination improvement of 5%. NRIs
were 27.48% and 22.3% for the 10% and 6%
intermediate-risk cut points for TBR measures
(Tables 2 and 3), respectively. A sensitivity anal-
ysis evaluating uncorrected FDG uptake demon-
strated that SUVmax also improved reclassiﬁcation(although not as well as TBR), whereas SUVmean
was ineffective (Online Table S5).
D I SCUSS ION
Our investigations yielded several important obser-
vations. First, we demonstrated a signiﬁcant asso-
ciation between aortic FDG uptake and incident
CVD. Second, we observed that the addition of
arterial FDG measures to traditional risk factors
improved discrimination of subsequent CVD risk.
Third, we observed that increasing arterial FDG-
PET signals are inversely associated with the
timing of CVD. Taken together, we demonstrated
that the FDG-PET/CT signal measured within the
Figure 4. Association
The bar graphs show
developed CVD at 0 to
79 months, respective
related to the time in
was 0.096 (p < 0.00
Figure 3. Proportion Free of CVD Stratiﬁed by TBR Tertiles
The p values from Kaplan-Meier survival curves were derived from log-rank test. Hazard
ratios were derived from Cox proportional hazards regression. Values were adjusted for age,
current smoking, hypertension, and hyperlipidemia, variables that showed signiﬁcant as-
sociation with CVD on univariate analysis from among established CV risk factors (age, sex,
hypertension, diabetes, current smoking, and hyperlipidemia) and body mass index. The
TBR was categorized based on the tertile distribution of the full cohort. HR ¼ hazard ratio;
other abbreviations as in Figures 1 and 2.
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1256arterial wall provides added information that is
useful for evaluating CVD risk in individuals who
are undergoing routine FDG-PET/CT scans for
oncological evaluation.
This arterial signal likely represents inﬂamma-
tory activity within the artery wall. FDG uptake
reﬂects the rate of glycolysis, which is particularly
increased in activated proinﬂammatory macro-
phages (24,25) and FDG avidly accumulates as aBetween Vascular Inﬂammation and Timing of CV Events
the average TBR (SD) in each of the groups of individuals who
6 months, 7 to 24 months, and >24 to 79 months and no events in
ly. On linear regression analysis, aortic FDG uptake (TBR) was inversely
terval between PET imaging and subsequent CVD, beta coefﬁcient
01). Error bars represent SD. Abbreviations as in Figures 1 and 2.result (26,27). FDG accumulation in the arterial
wall localizes to macrophage-rich regions and
correlates with immunohistochemical staining and
gene expression for macrophage-speciﬁc markers
(9,16,28), as well as circulating markers of
inﬂammation (13,29). Further, arterial FDG up-
take increases in proportion to atherosclerotic risk
factors (30,31), with plaque morphological
complexity (32), and after atherothrombotic events
(8,33,34). Further, several studies have demon-
strated that arterial FDG uptake is reduced by
statins (35) and by drugs that are thought to
inhibit inﬂammatory pathways (17,18).
The information provided by the PET/CT signal
may be distinct from that provided by circulating
biomarkers of inﬂammation. In this study, the
observed adjusted risk (beyond FRS) for persons in
the highest (vs. lowest) TBR tertile was approxi-
mately 3-fold greater compared with what has been
historically observed for the inﬂammatory blood
biomarker, high-sensitivity C-reactive protein
(hs-CRP) (3). Further, the PET/CT signal pro-
vided a substantially higher NRI (22% to 27%) than
that reported for hs-CRP (5.6% in the Framingham
Heart Study [3] and 5.7% in the Women’s Health
Study [5]) or other blood biomarkers (6,7). It is
possible that imaging (vs. blood) biomarkers provide
additional prognostic information that is more
relevant to the artery wall per se, whereas currently
used blood biomarkers carry information from
vascular as well as nonvascular sources.
Furthermore, PET/CT-measured arterial inﬂam-
mation strongly predicted and signiﬁcantly improved
CVD risk discrimination beyond traditional risk fac-
tors (FRS). Additionally, our results demonstrated
that the link between the PET signal and CVD was
independent of the effects of CAC score on both the
CVD outcomes and arterial inﬂammation. However,
it is important to note that the CACmeasurements in
this study were derived from attenuation-correction
computed tomography (ACCT) scans. Although
CAC measurements obtained from ACCT scans
have been shown to correlate well with those derived
from dedicated CAC scans, the sensitivity for
detection of low calcium values from nongated CT
scans is reduced. Accordingly, the data from this
study regarding the interrelationship between CAC
score and PET imaging signal as they pertain to CVD
risk should be interpreted cautiously.
The current study has several strengths. First, we
blindly analyzed images that were obtained during
routine PET/CT imaging, yet excluded only 2% of
images (11 of 527) due to inadequacy of image
quality, thus demonstrating that the majority of
Table 3. Reclassiﬁcation of Patients Without CVD at Index FDG-PET Who
Did and Did Not Develop CVD
Framingham Risk Variables*
(Model A)
Framingham Risk Variables D
FDG Uptake (TBR) (Model B)
<10% risk
n (%)
10%–20% risk
n (%)
>20% risk
n (%) Total
Participants with subsequent CVD
<10% risk 3 0 0 3
10%–20% risk 0 2 (25.00) 6 (75.00) 8
>20% risk 0 0 29 (100.00) 29
Total 3 2 35 40
Participants without subsequent CVD
<10% risk 103 (96.26) 3 (2.80) 1 (0.93) 107
10%–20% risk 29 (50.00) 19 (32.76) 10 (17.24) 58
>20% risk 1 (1.82) 15 (27.27) 39 (70.91) 55
Total 133 37 50 220
*Framingham risk variables included age (continuous), male or female sex (binary), current smoking
(binary), presence or absence of diabetes (binary), total cholesterol (continuous), high-density lipoprotein
(continuous), systolic blood pressure (continuous), and antihypertensive therapy (binary); TBR was modeled
as a continuous variable.
Abbreviations as in Table 1.
Table 2. Summary of Net Reclassiﬁcation Among Patients With Complete
Framingham Risk Variables
Risk
Categories
NRI (95%
Bootstrap CI)
(FRS D TBR)
Proportion
(Events) Correctly
Reclassiﬁed
Proportion
(Nonevents)
Correctly
Reclassiﬁed
<10%; 10%–20%; >20% 27.48% (16.27–39.92) 12.66% 14.82%
<6%; 6%–20%; >20% 22.3% (11.54–35.42) 12.31% 9.99%
TBR was modeled as continuous variable.
CI ¼ conﬁdence interval; NRI ¼ net reclassiﬁcation improvement; other abbreviations as in Table 1.
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1257routinely derived PET/CT examinations are of
sufﬁcient quality to produce this measure of CVD
risk. Further, by including all consecutive patients
that met our pre-speciﬁed criteria, this study pro-
vided a representative sample of cancer-free patients
undergoing cancer surveillance and supports the
generalizability of these ﬁndings to this population.
Additionally, the current study extends the
ﬁndings of Rominger et al. (10) in 2 important
ways. Although Rominger et al. (10) showed that
the PET signal was associated with subsequent
vascular events in a population of patients with
active cancer, we demonstrated that: 1) FDG up-
take, measured using PET/CT, strongly predicted
subsequent CVD independently of traditional risk
factors; and 2) this observation extended to in-
dividuals who were not receiving cancer chemo-
therapy. Furthermore, we demonstrated that the
signal can be derived by measuring the aorta alone
(as compared with measuring both the aorta and
carotids, which is technically more challenging).
Moreover, we showed that the arterial imaging
data provide an opportunity to reclassify patient
risk for CV events.
Study limitations. Several limitations primarily
associated with the retrospective nature of the
study should be noted. First, the fact that the
study’s sample population was drawn from a clin-
ical database (the majority of whom are cancer
survivors) limits the generalizability of these ﬁnd-
ings beyond that population. Further, given that
the patients who were studied were not prospec-
tively recruited, there is a limited opportunity to
compare the imaging ﬁndings with additional
blood biomarkers that are related to CV risk (such
as CRP). Additionally, the data used to adjudicate
events were limited to that contained within the
medical record; hence, some events might have
been missed or misclassiﬁed. Nonetheless, it is
anticipated that this would lead to an overall un-
derestimation of the technique’s prognostic value.
Furthermore, the use of clinically derived PET and
CT images does not take advantage of methods
that have been used to optimize the arterial FDG
signal. Notably, image acquisition at 1 h after
tracer injection (which is typically done for routine
clinical examinations) may be rather early for
arterial wall imaging because some (8,15) but not
all (36) prior studies have suggested an enhanced
ability to measure arterial wall activity at 3 (vs. 1) h
after FDG injection.
Taken together, the results of the present study
underscore the potential clinical utility of FDG-
PET measurement of arterial activity to enhancethe delineation of CVD risk in individuals un-
dergoing oncological evaluation and surveillance,
particularly cancer survivors. In this population,
FDG-PET imaging is routinely performed; thus, it
may be reasonable to take advantage of the readily
available information to help guide clinicians in
their preventive and management strategies without
the need to add imaging costs or burden of addi-
tional radiation exposure. Furthermore, the sub-
population of cancer survivors has grown
substantially over the years (37) and CVD has
become a leading cause of morbidity and mortality
in this subpopulation (38,39). Accordingly, the
derivation of risk stratiﬁcation data from routine
PET/CT images may be of considerable utility in
this group.
Additionally, the present result further supports
the use of PET/CT imaging to evaluate the efﬁcacy
of novel therapies that target atherosclerotic
inﬂammation (19,40). However, further validation
is needed to assess whether this imaging approach is
Figueroa et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 2 , 2 0 1 3
Arterial Inﬂammation and CV Risk D E C E M B E R 2 0 1 3 : 1 2 5 0 – 9
1258sufﬁciently valuable to outweigh the associated cost
(Medicare reimbursement rate of approximately
$1,160) and risks (such as radiation exposure of up
to 7 mSv) in other groups of patients who would not
otherwise undergo PET/CT imaging for pre-
existing clinical indications.
CONCLUS IONS
FDG-PET–measured arterial inﬂammation sub-
stantially improved CVD event prediction and risk
stratiﬁcation beyond FRS in a population of cancer-free participants undergoing cancer surveillance
without prior history of clinical CVD. These data
also suggest that routinely derived PET/CT images
contain data that could be mined to improve the CV
risk stratiﬁcation of cancer survivors, and after
further study, may prove useful in additional
populations.
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